NCT04454658 2025-07-16
Safety and Tolerability Study of Oral ABBV-744 Tablet Alone or in Combination With Oral Ruxolitinib Tablet or Oral Navitoclax Tablet in Adult Participants With Myelofibrosis
AbbVie
Phase 1 Active not recruiting
AbbVie
AbbVie
AbbVie
National Cancer Institute (NCI)
AbbVie
AbbVie
AbbVie